# US 2019/0315699 A1 · Selective sulfonation of benzodiazepine derivatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0315699 A1
- Document ID: US20190315699A1
- Status: Published application
- Kind: A1
- Application number: 16/364,801
- Filed: 2019-03-26
- Published: 2019-10-17
- Earliest claimed: 2016-11-23
- Assignees: ImmunoGen, Inc.
- Applicants: Immunogen, Inc.
- Inventors: Scott A. Hilderbrand; Benjamin M. Hutchins
- Web page: https://patentgrep.com/patent/US20190315699A1

## CPC

- C07D 243/26: Preparation from compounds already containing the benzodiazepine skeleton
- A61K 47/6803: {Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates}
- A61K 47/68035: {the drug being a pyrrolobenzodiazepine}
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- C07D 487/04: Ortho-condensed systems
- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- C07K 16/30: from tumour cells
- C07K 2317/526: CH3 domain
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The invention relates to novel methods of preparing cell-binding agent-cytotoxic agent conjugates, wherein the cytotoxic agent is an imine-containing cytotoxic agent bearing a maleimide group. In some embodiments, the cell-binding agent (CBA) is covalently linked to the cytotoxic agent through an engineered Cys, such as an engineered Cys in the heavy chain CH3 domain, at a position corresponds to the EU/OU numbering position 442 (or C442) on an antibody CBA. The invention also provides conjugates prepared by the methods of the present invention, compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the conjugates of the invention.

## Claims

### Claim 1

A method of preparing a cell-binding agent-cytotoxic agent conjugate comprising the steps of:
(a) reacting an imine-moiety in an imine-containing cytotoxic agent represented by the following formula:
or a pharmaceutically acceptable salt thereof, with sulfur dioxide, a bisulfite salt or a metabisulfite salt in an aqueous solution in the absence of a buffer to form a modified cytotoxic agent comprising a modified imine moiety represented by the following formula:
or a pharmaceutically acceptable salt thereof; and
(b) reacting the modified cytotoxic agent with a cell-binding agent to form the cell-binding agent-cytotoxic agent conjugate,
wherein D is an imine-containing benzodiazepine compound; and L is a linker.

### Claim 2 (depends on 1)

The method of claim 1, wherein 0.5 to 5 equivalents of the bisulfite salt or 0.25 to 2.5 equivalents of the metabisulfite salt is reacted with 1 equivalent of the imine-containing cytotoxic agent;
0.8 to 2.0 equivalents of the bisulfite salt or 0.4 to 1.0 equivalents of the metabisulfite salt is reacted with 1 equivalent of the imine-containing cytotoxic agent;
1.1 to 1.6 equivalents of the bisulfite salt or 0.55 to 0.8 equivalents of the metabisulfite salt is reacted with 1 equivalent of the imine-containing cytotoxic agent; or
wherein 1.4 equivalents of the bisulfite salt or 0.7 equivalent of the metabisulfite salt is reacted with 1 equivalent of the imine-containing cytotoxic agent.

### Claim 3 (depends on 1)

The method of claim 1, wherein the reaction of step (a) is carried out in a mixture of an organic solvent and water.

### Claim 4 (depends on 3)

The method of claim 3, wherein the reaction of step (a) is carried out in a mixture of dimethylacetamide (DMA) and water.

### Claim 5 (depends on 1)

The method of claim 1, wherein in step (a), the imine-containing cytotoxic agent is reacted with sodium bisulfite or sodium metabisulfite.

### Claim 6 (depends on 1)

The method of claim 1, wherein the modified cytotoxic agent is not purified before reacting with the cell-binding agent in step (b).

### Claim 7 (depends on 1)

The method of claim 1, wherein the reaction of step (b) is carried out at a pH of 4 to 9, a pH of 5 to 8.5, or a pH of 5.5 to 6.5.

### Claim 8 (depends on 1)

The method of claim 1, wherein D is an imine-containing indolinobenzodiazepine compound.

### Claim 9 (depends on 1)

The method of claim 1, wherein D is represented by the following formula:
or a pharmaceutically acceptable salt thereof, wherein:
one of L′, L″, and L′″ is represented by the following formula:
—Z1-P1-Z2—Rx1—C(═O)— (A′), or
—N(Re)—Rx1—C(═O)— (D′);
and the other two are each independently selected from —H, an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms, a polyethylene glycol unit —(CH2CH2O)n—Rc, halogen, guanidinium [—NH(C═NH)NH2], —OR, —NR′R″, —NO2, —NR′COR″, —SR, —SOR′, —SO2R′, —SO3H, —OSO3H, —SO2NR′R″, cyano, an azido, —COR′, —OCOR′, and —OCONR′R″;
one of the Z1 and Z2 is —C(═O)—, and the other is —NR5—;
P1 is an amino acid residue or a peptide containing between 2 to 20 amino acid residues;
Rx1 is an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms;
Re is —H, a linear, branched or cyclic alkyl, alkenyl or alkynyl having 1 to 10 carbon atoms or —(CH2—CH2—O)n—Rk, wherein Rk is a —H, a linear, branched cyclic alkyl having 1 to 6 carbon atoms, optionally bearing a secondary amino (e.g., —NHR101) or tertiary amino (—NR101R102) group or a 5- or 6-membered nitrogen containing heterocycle, wherein R101 and R102 are each independently a linear, branched, or cyclic alkyl, alkenyl or alkynyl having 1 to 10 carbon atoms;
R, for each occurrence, is independently selected from the group consisting of —H, an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms, a polyethylene glycol unit —(CH2CH2O)n—Rc, an optionally substituted aryl having 6 to 18 carbon atoms, an optionally substituted 5- to 18-membered heteroaryl ring containing one or more heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an optionally substituted 3- to 18-membered heterocyclic ring containing 1 to 6 heteroatoms independently selected from O, S, N and P;
R′ and R″ are each independently selected from —H, —OH, —OR, —NHR, —NR2, —COR, an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms, a polyethylene glycol unit —(CH2CH2O)n—Rc, and an optionally substituted 3- to 18-membered heterocyclic ring having 1 to 6 heteroatoms independently selected from O, S, N and P;
Rc is —H or an optionally substituted linear or branched alkyl having 1 to 4 carbon atoms;
n is an integer from 1 to 24;
X1′ is selected from —H, an amine-protecting group, an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms, a polyethylene glycol unit —(CH2CH2O)n—Rc, an optionally substituted aryl having 6 to 18 carbon atoms, an optionally substituted 5- to 18-membered heteroaryl ring containing one or more heteroatoms independently selected from nitrogen, oxygen, and sulfur, and an optionally substituted 3- to 18-membered heterocyclic ring containing 1 to 6 heteroatoms independently selected from O, S, N and P;
Y1′ is selected from —H, an oxo group, an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms, an optionally substituted 6- to 18-membered aryl, an optionally substituted 5- to 18-membered heteroaryl ring containing one or more heteroatoms independently selected from nitrogen, oxygen, and sulfur, an optionally substituted 3- to 18-membered heterocyclic ring having 1 to 6 heteroatoms;
R1, R2, R3, R4, R1′, R2′, R3′ and R4′ are each independently selected from the group consisting of —H, an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms, a polyethylene glycol unit —(CH2CH2O)n—Rc, halogen, guanidinium [—NH(C═NH)NH2], —OR, —NR′R″, —NO2, —NCO, —NR′COR″, —SR, —SOR′, —SO2R′, —SO3−H, —OSO3H, —SO2NR′R″, cyano, an azido, —COR′, —OCOR′, and —OCONR′R″;
R6 is —H, —R, —OR, —SR, —NR′R″, —NO2, or halogen;
G is —CH— or —N—;
A and A′ are the same or different, and are independently selected from —O—, oxo (—C(═O)—), —CRR′O—, —CRR′—, —S—, —CRR'S—, —NR5 and —CRR′N(R5)—; and
R5 for each occurrence is independently —H or an optionally substituted linear or branched alkyl having 1 to 10 carbon atoms.

### Claim 10 (depends on 9)

The method of claim 9, wherein L″ and L″ ′ are both —H′; and L′ is represented by the following formula:
—NR5-P1-C(═O)—(CRaRb)s—C(═O)— (B1′);
—NR5-P1—C(═O)-Cy-(CRaRb)s1′—C(═O)— (B2′);
—C(═O)-P1-NR5—(CRaRb)s—C(═O)— (C1′), or
—C(═O)-P1-NR5-Cy-(CRaRb)s1′—C(═O)— (C2′)
wherein:
Ra and Rb, for each occurrence, are each independently —H, (C1-C3)alkyl or a charged substituent or an ionizable group Q;
s is an integer from 1 to 6;
s1′ is 0 or an integer from 1 to 6; and
Cy is a cyclic alkyl having 5 or 6 ring carbon atoms optionally substituted with halogen, —OH, (C1-C3)alkyl, (C1-C3)alkoxy, or halo(C1-C3)alkyl.

### Claim 11 (depends on 9)

The method of claim 9, wherein:
R1, R2, R3, R4, R1′, R2′, R3′ and R4′ are all —H;
R6 is —OMe;
X1′ and Y1′ are both —H; and
A and A′ are —O—.

### Claim 12 (depends on 1)

The method of claim 1, wherein -L- is represented by the following structural formula:
or a pharmaceutically acceptable salt thereof, wherein:
s1 is the site covalently linked to D; s2 is the site covalently linked to the maleimide group;
R23 and R24, for each occurrence, are independently H or an optionally substituted alkyl;
m′ is an integer between 0 and 10; and
Rh′ is H or an optionally substituted alkyl.

### Claim 13 (depends on 1)

The method of claim 1, wherein the imine-containing cytotoxic agent is represented by the following formula:
or a pharmaceutically acceptable salt thereof, and the modified cytotoxic agent is represented by the following formula:
or a pharmaceutically acceptable salt thereof.

### Claim 14 (depends on 1)

The method of claim 1, wherein D is represented by the following formula:
or a pharmaceutically acceptable salt thereof, wherein:
X′ is selected from the group consisting of —H, —OH, a substituted or unsubstituted linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms, phenyl, and an amine-protecting group;
Y′ is selected from the group consisting of —H, an oxo group, a substituted or unsubstituted linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms;
A and A′ are selected from —O— and —S—;
W′ is absent, or selected from —O—, —N(Re)—, —N(Re)—C(═O)—, —N(C(═O)Re)—, —S— or —CH2—S—, —CH2NRe—;
Rx is absent or selected from a linear, branched or cyclic alkyl having 1 to 10 carbon atoms;
Re is —H, a linear, branched or cyclic alkyl, alkenyl or alkynyl having 1 to 10 carbon atoms or —(CH2—CH2—O)n—Rk, wherein Rk is a —H, a linear, branched cyclic alkyl having 1 to 6 carbon atoms, optionally bearing a secondary amino (e.g., —NHR101) or tertiary amino (—NR101R102) group or a 5- or 6-membered nitrogen containing heterocycle, wherein R101 and R102 are each independently a linear, branched, or cyclic alkyl, alkenyl or alkynyl having 1 to 10 carbon atoms;
n is an integer from 1 to 24;
G is selected from —CH— or —N—;
R6 is —H, —R, —OR, —SR, —NR′R″, —NO2, or halogen; and
R is —H, an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms or a PEG group —(CH2CH2O)n—Rc, wherein n is an integer from 1 to 24, and Rc is a linear or branched alkyl having 1 to 4 carbon atoms;
R′ and R″ are each independently selected from —H, —OH, —OR, —NRRg′, —COR, an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms, an optionally substituted aryl having from 6 to 18 carbon atoms, an optionally substituted 3- to 18-membered heterocyclic ring having 1 to 6 heteroatoms selected from O, S, N and P, a PEG group —(CH2CH2O)n—Rc, and Rg′ is —H, an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms or a PEG group —(CH2CH2O)n—Rc.

### Claim 15 (depends on 14)

The method of claim 14, wherein D is represented by the following structural formula:
or a pharmaceutically acceptable salt thereof.

### Claim 16 (depends on 14)

The method of claim 14, wherein:
X′ and Y′ are both —H;
A and A′ are both —O—;
R6 is —OMe;
W′ is —N(Re)— or —N(Re)—C(═O)—;
Re is —H, a linear or branched alkyl having 1 to 4 carbon atoms or —(CH2—CH2—O)n—Rk wherein Rk is a —H, a linear or branched alkyl having 1 to 4 carbon atoms;
n is an integer from 2 to 6; and
Rx is a linear or branched alkyl having 1 to 6 carbon atoms.

### Claim 17 (depends on 14)

The method of claim 14, wherein D is represented by the following structural formula:
or a pharmaceutically acceptable salt thereof.

### Claim 18 (depends on 1)

The method of claim 1, wherein D is an imine-containing pyrrolobenzodiazepine (PBD) compound.

### Claim 19 (depends on 1)

The method of claim 1, wherein D is represented by the following formula:
or a pharmaceutically acceptable salt thereof, wherein:
W is selected from C═O, C═S, CH2, BH, SO and SO2;
X1′ is selected from —H, an amine-protecting group, an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms, a polyethylene glycol unit —(CH2CH2O)n—Rc, an optionally substituted aryl having 6 to 18 carbon atoms, an optionally substituted 5- to 18-membered heteroaryl ring containing one or more heteroatoms independently selected from nitrogen, oxygen, and sulfur, and an optionally substituted 3- to 18-membered heterocyclic ring containing 1 to 6 heteroatoms independently selected from O, S, N and P;
Y1′ is selected from —H, an oxo group, an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms, an optionally substituted 6- to 18-membered aryl, an optionally substituted 5- to 18-membered heteroaryl ring containing one or more heteroatoms independently selected from nitrogen, oxygen, and sulfur, an optionally substituted 3- to 18-membered heterocyclic ring having 1 to 6 heteroatoms;
R6 is —H, —R, —OR, —SR, —NR′R″, —NO2, or halogen;
A and A′ are the same or different, and are independently selected from —O—, oxo (—C(═O)—), —CRR′O—, —CRR′—, —S—, —CRR'S—, —NR5 and —CRR′N(R5)—,
R, for each occurrence, is independently selected from the group consisting of —H, an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms, a polyethylene glycol unit —(CH2CH2O)n—Rc, an optionally substituted aryl having 6 to 18 carbon atoms, an optionally substituted 5- to 18-membered heteroaryl ring containing one or more heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an optionally substituted 3- to 18-membered heterocyclic ring containing 1 to 6 heteroatoms independently selected from O, S, N and P;
R′ and R″ are each independently selected from —H, —OH, —OR, —NHR, —NR2, —COR, an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms, a polyethylene glycol unit —(CH2CH2O)n—Rc, and an optionally substituted 3- to 18-membered heterocyclic ring having 1 to 6 heteroatoms independently selected from O, S, N and P;
Rc is —H or a substituted or unsubstituted linear or branched alkyl having 1 to 4 carbon atoms, or the linking group with the reactive group bonded thereto;
n is an integer from 1 to 24;
R5 for each occurrence is independently —H or an optionally substituted linear or branched alkyl having 1 to 10 carbon atoms;
D0 and D0′ are the same or different, and are independently absent or selected from the group consisting of an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl having 1 to 10 carbon atoms, an amino acid, a peptide bearing 2 to 6 amino acids, and a polyethylene glycol unit (—OCH2CH2)n—;
L is absent, a linker, a polyethylene glycol unit (—OCH2CH2)n—, an optionally substituted linear, branched or cyclic alkyl or alkenyl having 1 to 10 carbon atoms, an optionally substituted phenyl group, an optionally substituted 3 to 18-membered heterocyclic ring or a 5- to 18-membered heteroaryl ring having 1 to 6 heteroatoms independently selected from O, S, N and P;
Ra, Ra′, Rb and Rb′ are the same or different, and are independently selected from the group consisting of —H, halide, or an optionally substituted branched, linear or cyclic alkyl having 1 to 10 carbon atoms; or Ra and Ra′ and/or Rb and Rb′ together form a double bond containing group =B and =B′ respectively;
=B and =B′ are the same or different and independently selected from an optionally substituted branched or linear alkenyl or a carbonyl group;
Q is Q1-Ar-Q2;
Q′ is Q1′-Ar′-Q2′;
Q1 and Q1′ are each independently absent, a linear, branched or cyclic alkyl from 1 to 6 carbon atoms or a —CH═CH unit;
Ar and Ar′ are each independently absent, or represent an aryl group;
Q2 and Q2′ are each independently selected from —H, a linker, a substituted or unsubstituted linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms, a polyethylene glycol unit —Rc′—(OCH2CH2)n—Rc, or a substituent selected from a halogen, guanidinium [—NH(C═NH)NH2], —R, —OR, —NR′R″, —NO2, —NCO, —NR′COR″, —NR′(C═O)OR″, —SR, a sulfoxide represented by —SOR′, a sulfone represented by —SO2R′, a sulfonate —SO3M, a sulfate —OSO3M, a sulfonamide represented by SO2NR′R″, cyano, an azido, —COR′, —OCOR′ or —OCONR′R″; and
Rc′ is absent or selected from linear or branched alkyl, alkenyl or alkynyl having 1 to 5 carbon atoms.

### Claim 20 (depends on 1)

The method of claim 1, wherein the imine-containing cytotoxic agent is represented by the following formula:
or a pharmaceutically acceptable salt thereof, wherein:
the dotted lines indicate the optional presence of a double bond;
R3″ is a C3-12 alkylene group,
each X′, for each occurrence, is independently —O—, —S— or —N(H)—
each R2 is independently selected from —H, —OH, —CN, —R1′, —OR1′, —O—SO2—R1′′, —CO2R1′, —COR1′, or halo, or both R2 taken together, are ═O, ═CH2, ═CH—Ra, or ═C(Ra)2;
each R2′ is independently selected from —H, —OH, —CN, —R1′, —OR1′, —O—SO2—R1′, —CO2R1′, —COR1′ or halo;
R4b is a leaving group selected from —OR6′, —OCOR4′, —OCOOR4′, —OCONR4′R5′, —NR4′R5′, —NR4′COR5′, —NR4′NR4′R5′, an optionally substituted 5- or 6-membered nitrogen-containing heterocycle (e.g., piperidine, tetrahydropyrrole, pyrazole, morpholine), a guanidinum represented by —NR4′(C═NH)NR4′R5′, an amino acid, or a peptide represented by —NR6′COP′, wherein P′ is an amino acid or a polypeptide containing between 2 to 20 amino acid units, —SR6′, —SOR4′, —SO2M, —SO3M, —OSO3M, halogen, cyano and an azido;
RL is linker bearing a maleimide moiety that can form a covalent bond with a cell binding agent (CBA);
R6 and R9 are independently selected from —H, —R1, —OH, —OR1, —SH, —SR1, —NH2, —NHR1′, —NR1′R3′, —NO2, Me3Sn and halo; and,
R1′ and R3′ are each independently selected from optionally substituted C1-12 alkyl, C3-20 heterocyclyl or C5-20 aryl groups, and optionally in relation to the group —NR1′R3′, R1′ and R3′ together with the nitrogen atom to which they are attached form an optionally substituted 4-, 5-, 6- or 7-membered heterocyclic ring; or any pair of adjacent groups from R6 to R9 together form a group —O—(CH2)p—O—, where p is 1 or 2;
R4′ and R5′ are each independently selected from —H, —OH, —OR6′, —NHR6′, —NR6′2, —COR6′ an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms, a polyethylene glycol unit —(CH2CH2O)n—Rb, or an optionally substituted 3-18-membered heterocyclic ring having 1 to 6 heteroatoms independently selected from O, S, N or P;
R6′, for each occurrence, is independently selected from the group consisting of —H, an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms, a polyethylene glycol unit —(CH2CH2O)n—Rb, an optionally substituted aryl having 6 to 18 carbon atoms, an optionally substituted 5- to 18-membered heteroaryl ring containing one or more heteroatoms independently selected from nitrogen, oxygen, or sulfur, and an optionally substituted 3- to 18-membered heterocyclic ring containing 1 to 6 heteroatoms independently selected from O, S, N or P;
Ra is independently selected from —R1, —CO2R1′, —COR140, —CHO, —CO2H, or halo;
Rb is —H or a substituted or unsubstituted linear or branched alkyl having 1 to 4 carbon atoms;
M is H or a pharmaceutically acceptable cation; and
n is an integer from 1 to 24.
